Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Automated retinal scans for early detection of diabetic eye diseases through use of artificial intelligence

Project description

Retinal screening device for earlier, easier diabetes diagnosis

Most of us take our sight for granted, but a growing population is at risk of severe vision impairment and even blindness, in large part due to the growing incidence of diabetes and the potential accompanying development of diabetic retinopathy. As with many conditions and diseases, early diagnosis and treatment can significantly improve outcome. However, current screening methods are expensive, require highly trained professional expertise, and are largely inaccessible to patients in developing countries. The EU-funded iScan project has developed an easy and affordable point-of-care retinal screening device that could be used by primary care physicians or even pharmacists. Integrating a camera, image-processing software, machine learning, and artificial intelligence, the solution promises to significantly increase early retinal screening and enhance outcomes for millions.

Objective

Oivi’s mission is to provide affordable eye care for all. Our vision is to eliminate unnecessary blindness by providing a lowcost camera for retinal (fundus) photography, with fully automated image capture and diagnostics. Our goal is for Oivi to become the point-of-care device for preventative eye screening, with diabetic retinopathy (DR) as our first area of focus. DR affects >160 million people worldwide and is the most common cause of blindness among people with diabetes. However, early detection and intervention can successfully prevent vision-loss from DR in 95% of the cases. A major financial and social burden is caused by DR, and these costs can be vastly reduced through a solution like Oivi.

Current solutions for DR screening are often expensive and require extensive training, limiting accessibility for patients, especially in developing countries. Oivi’s device is a unique combination of automated, easy-to-use, low-cost and integrated AI diagnostics solutions in a highly portable design. These features will allow healthcare professionals and pharmacists to carry out screening anywhere with no training and address the unmet need for early screening in primary care.

Oivi will be particularly relevant for low- and middle-income countries like India, but also for the European market. Oivi envisions to move the standard of care of diagnosis of DR from the ophthalmologists office to primary care level. This leads to a smooth patient flow between primary care and specialists and reduces patient fall out. Also, pharmacies provide excellent coverage and can make DR screening as common as blood glucose tests.

Oivi will use the iScan project as a vital step to prepare the company’s business strategy and mature the device and its diagnostic functionalities and to align it with end-user needs, regulatory standards and IP strategy. The iScan project is expected to untap a large business opportunity for Oivi, in the first application – DR screening and diagnosis.

Programme(s)

Topic(s)

Funding Scheme

SME-1 - SME instrument phase 1

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

OIVI AS
Net EU contribution
€ 50 000,00
Address
GAUSTADALLEEN 21
0349 Oslo
Norway
SME
Yes
Region
Norge Oslo og Viken Oslo
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00